跳至主要内容
临床试验/jRCT2031230526
jRCT2031230526招募中不适用

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis with Polyangiitis

Nippon Shinyaku Co., Ltd.0 个研究点目标入组 45 人开始时间: 2024年5月29日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
45
主要终点
The proportion of subjects in remission (oral glucocorticoid [OGC] 4.0)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized Controlled Trial
干预模型
Parallel Assignment
主要目的
Treatment Purpose
盲法
Double Blind

入排标准

年龄范围
18age old over 至 No limit(—)
性别
All

入选标准

  • (1)Male or female subjects aged >=18 years at the time the informed consent form is signed
  • (2)Diagnosis of EGPA
  • (3)Subjects receive background OGC dose of>=7.5 mg/day with or without stable treatment with mepolizumab or benralizumab.

排除标准

  • (1) Current diagnosis of either granulomatosis with polyangiitis or microscopic polyangiitis
  • (2) Imminently life-threatening EGPA disease

结局指标

主要结局

The proportion of subjects in remission (oral glucocorticoid [OGC] 4.0)

时间窗: Week 28 of the study treatment period

Definition of remission (OGC 4.0): Birmingham Vasculitis Activity Score (BVAS) of 0 AND OGC dose of prednisolone/prednisone <=4.0 mg/day.

次要结局

未报告次要终点

研究者

相似试验